| DESCRIPTION | - BOXUS et al., J Virol, (20070000), vol. 81, pages 6879 - 89 | - |
| DESCRIPTION | - EL OUAHABI et al., FEBSLetts, (19960000), vol. 380, pages 108 - 12 | - |
| DESCRIPTION | - "Functional Polymer Colloids and Microparticles", Microspheres, microcapsules & liposomes, Citus Books, (20020000), vol. 4 | - |
| DESCRIPTION | - GIULIANI et al., Proc Natl Acad Sci USA, (20060000), vol. 103, no. 29, pages 10834 - 9 | - |
| DESCRIPTION | - Handbook of Experimental Immunology,, Blackwell Scientific Publications, (19860000), vol. I-IV | - |
| DESCRIPTION | - "harmaceutical Nanocarriers: Methods and Protocols", Liposomes: Methods and Protocols,, Humana Press, (20090000), vol. 1 | - |
| DESCRIPTION | - HEYES et al., J Controlled Release, (20050000), vol. 107, pages 276 - 87 | - |
| DESCRIPTION | - HOEKSTRA et al., Biochimica et Biophysica Acta, (20040000), vol. 1660, pages 41 - 52 | - |
| DESCRIPTION | - JEFFS et al., Pharmaceutical Research, (20050000), vol. 22, no. 3, pages 362 - 372 | - |
| DESCRIPTION | - JOHANNING et al., Nucleic Acids Res, (19950000), vol. 23, pages 1495 - 1501 | - |
| DESCRIPTION | - MAURER et al., Biophysical Journal,, (20010000), vol. 80, pages 2310 - 2326 | - |
| DESCRIPTION | - PERRI et al., J Virol, (20030000), vol. 77, pages 10394 - 10403 | - |
| DESCRIPTION | - ROMBERG et al., Pharmaceutical Research, (20080000), vol. 25, pages 55 - 71 | - |
| DESCRIPTION | - TAYLOR et al., Vaccine, (20050000), vol. 23, pages 1242 - 50 | - |
| DESCRIPTION | - YONEYAMAFUJITA, Cytokine & Growth Factor Reviews, (20070000), vol. 18, pages 545 - 51 | - |
| OPPOSITION | - Anonymous, "Spikevax1 (COVID-19 mRNA Vaccine (nucleoside modified)), EMA/765306/2022 EMEA/H/C/005791", EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH, (20220101), pages 1 - 5, XP093045427 | - |
| OPPOSITION | - Anonymous, "Zika vaccine (mRNA-1325 and mRNA-1893)", Excerpt from Moderna's 2018 10-K, (20180101), pages 1 - 4, XP093045397 | - |
| OPPOSITION | - Chowdary Tirumala K, Et Al, "Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL", Nature Structural & Molecular Biology, (20100701), vol. 17, no. 7, pages 882 - 889, XP093031567 | - |
| OPPOSITION | - Collins P L, "Human Respiratory Syncytial Virus", Encyclopedia of Virology, (20080101), pages 543 - 550, XP093031553 | - |
| OPPOSITION | - Di Giovane Paolo, Et Al, "Structure of Herpes Simplex Virus Glycoprotein D Bound to the Human Receptor Nectin-1", PLoS Pathogens, (20110901), vol. 7, no. 9, pages 1 - 13, XP093031730 | - |
| OPPOSITION | - Dolgin Elie, "TRIAL SETTLES DEBATE OVER BEST DESIGN FOR MRNA IN COVID VACCINES", Nature, Springer Nature Limited, (20230119), pages 419 - 420, XP093045416 | - |
| OPPOSITION | - Duggan Sean T, Plosker Greg L, "Intanza® 15 µg Intradermal Seasonal Influenza Vaccine", Drugs Aging, (20100701), vol. 27, no. 7, pages 597 - 605, XP093031560 | - |
| OPPOSITION | - Feldman Steven A, Et Al, "The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate", Journal of Virology, (20000701), vol. 74, no. 14, pages 6442 - 6447, XP093031559 | - |
| OPPOSITION | - Fraenkel-Conrat Heinz, Kimball Paul, "Virology", Virology, PRENTICE-HALL, INC., Englewood Cliffs, N.J., (19820101), pages 35, 124 - 128-130, 285-292, 390, XP093046034 | - |
| OPPOSITION | - IMMORDINO et al., "Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential", Intl. J. Nanomed., (20060000), vol. 1, pages 297 - 315, XP009145524 | - |
| OPPOSITION | - Immordino Maria Laura; Dosio Franco; Cattel Luigi, "Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential", INTERNATIONAL JOURNAL OF NANOMEDICINE, DOVE MEDICAL PRESS LTD., AUCKLAND, NZ, AUCKLAND, NZ , (20060101), vol. 1, no. 3, ISSN 1176-9114, pages 297 - 315, XP009145524 | - |
| OPPOSITION | - Jiang Shibo, Et Al, "Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines", Emerging Microbes & Infections, (20120101), pages 1 - 9, XP093031731 | - |
| OPPOSITION | - KIMBERLY HASSETT, Declaration | - |
| OPPOSITION | - KLEMM et al., "Prevention of bacterial adhesion", Appl Microbiol Biotechnol, vol. 88, (20100808), pages 451 - 459, XP019841798 | - |
| OPPOSITION | - Lingwood Clifford A, Et Al, "The Role of Glycosphingolipids in HIV/AIDS", Discovery Medicine, (20110401), vol. 11, no. 59, pages 303 - 313, XP093031728 | - |
| OPPOSITION | - LINGWOOD et al., "Globotriaosyl ceramide receptor function - Where membrane structure and pathology intersect", FEBS Lett, (20100503), vol. 584, no. 9, pages 1879 - 86, XP027003146 | - |
| OPPOSITION | - Lowe Derek, "CureVac Comes Around", Science, (20230101), pages 1 - 3, XP093045422 | - |
| OPPOSITION | - MacLachlan I., "Liposomal formulations for nucleic acid delivery", MacLachlan I., CROOKE STANLEY T, ANTISENSE DRUG TECHNOLOGY:PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2ND ED., US , CRC PRESS , (20070101), pages 237 - 270, ISBN 978-0-8493-8796-8, XP002584305 | - |
| OPPOSITION | - Maurer Ulrike E, Et Al, "Native 3D intermediates of membrane fusion in herpes simplex virus 1 entry", Proceedings of the National Academy of Sciences, (20080729), vol. 105, no. 30, pages 10559 - 10564, XP093031565 | - |
| OPPOSITION | - Morrison Trudy G., "PARAMYXOVIRUSES, INFECTION AND IMMUNITY 1909", Encyclopedia of Immunology, (19980101), pages 1909 - 1916, XP093046089 | - |
| OPPOSITION | - Petri William A, Et Al, "Chapter 2: Microbial Adherence", Infectious Diseases, (20100101), pages 15 - 25, XP093031726 | - |
| OPPOSITION | - Suerbaum Sebastian, Burchard Gerd-Dieter, Kaufmann Stefan H. E., Schulz Thomas F., Medizinische Mikrobiologie und Infektiologie, Berlin, Heidelberg, Springer Berlin Heidelberg, (20200101), page 565, 635, ISBN 978-3-662-61385-6, XP093046043 | - |
| OPPOSITION | - VAN DEN BERG et al., "Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity", J Control Release, (20100125), vol. 141, no. 2, pages 234 - 40, XP026815097 | - |
| OPPOSITION | - VAN DEN BERG et al., "Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity", J. Contr. Release, (20100000), vol. 141, pages 234 - 240, XP026815097 | - |
| OPPOSITION | - "Virulence Factors of Bacterial and Viral Pathogens", OpenStax, Microbiology, (20230221), URL: https://openstax.org/books/microbiology /pages/15-3-vi rulence- factors-of- bacterial-and-viral-pathogens | - |
| OPPOSITION | - Weigele Peter R, "Homotrimeric, beta-Stranded Viral Adhesins and Tail Proteins", Journal of Bacteriology, (20030701), vol. 185, no. 14, pages 4022 - 4030, XP093031556 | - |
| OPPOSITION | - White David O, et al, "Medical Virology Fourth Edition ", Medical Virology, Academic Press, (19940101), ISSN 9780-127466422, page 3-29, 434-435, 450-459, 538-541, XP093046091 | - |
| OPPOSITION | - WIZEMANN et al., "Adhesins as Targets for Vaccine Development", Emerg Infect Dis, (19990500), vol. 5, no. 3, pages 395 - 403, XP002938711 | - |
| OPPOSITION | - WIZEMANN et al., "Adhesins as Targets for Vaccine Development", Emerging Infectious Diseases, (19990000), vol. 5, pages 395 - 403, XP002938711 | - |
| OPPOSITION | - WIZEMANN T M, ADAMOU J E, LANGERMANN S, "ADHESINS AS TARGETS FOR VACCINE DEVELOPMENT", EMERGING INFECTIOUS DISEASES, ATLANTA, GA, US, US , (19990501), vol. 05, no. 03, ISSN 1080-6059, pages 395 - 403, XP002938711 | - |
| OPPOSITION | - WIZEMANN T.M. et al, "ADHESINS AS TARGETS FOR VACCINE DEVELOPMENT", EMERGING INFECTIOUS DISEASES, ATLANTA, GA, US, US , (19990501), vol. 05, no. 03, ISSN 1080-6059, pages 395 - 403, XP002938711 | - |
| OPPOSITION | - Zemans Rachel L, "Chapter 10: Acute Respiratory Distress Syndrome", Lung Epithelial Biology in the Pathogenesis of Pulmonary Disease, (20170101), pages 185 - 209, XP093031724 | - |
| OPPOSITION | - PASCOLO, "Plasmid DNA and Messenger RNA for Therapy", Handbook of Pharmaceutical Biotechnology, Hoboken, NJ, USA, (20070000), XP055626043 | |
| OPPOSITION | - Shayne Cox, Steve Pascolo, "Chapter 7.2. Plasmid DNA and Messenger RNA for Therapy", Handbook of Pharmaceutical Biotechnology, John Wiley & Sons , (20070601), pages 971 - 1011, doi:10.1002/9780470117118.ch07b, ISBN 978-0-471-21386-4, XP055626043 | |
| OPPOSITION | - MARTINON et al., "Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome- entrapped mRNA", Eur. J. Immunol., (19930000), vol. 23, doi:10.1002/eji.1830230749, pages 1719 - 1722, XP002937540 | |
| OPPOSITION | - MARTINON et al., "Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA", Eur. J. Immunol, (19930000), vol. 23, doi:10.1002/eji.1830230749, pages 1719 - 1722, XP002937540 | |
| OPPOSITION | - MARTINON F, ET AL., "INDUCTION OF VIRUS-SPECIFIC CYTOTOXIC T LYMPHOCYTES IN VIVO BY LIPOSOME-ENTRAPPED MRNA", European Journal of Immunology, Wiley-VCH, Hoboken, USA, Hoboken, USA, (19930101), vol. 23, doi:10.1002/eji.1830230749, ISSN 0014-2980, pages 1719 - 1722, XP002937540 | |
| OPPOSITION | - LI et al., "Low -pH-sensitive poly(ethylene glycol) (PEG)-stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery", Journal of Gene Medicine, (20050000), vol. 7, doi:10.1002/JGM.634, pages 67 - 79, XP008126013 | |
| OPPOSITION | - ZHANG et al., "The Cytoplasmic Tails of the Influenza Virus Spike Glycoproteins Are Required for Normal Genome Packaging", Virology, (20000000), vol. 269, no. 2, doi:10.1006/viro.2000.0228, pages 325 - 334, XP004450270 | |
| OPPOSITION | - PASCOLO S., "Vaccination with messenger RNA (mRNA", Handb Exp Pharmacol, (20080000), doi:10.1007/978-3-540-72167-3_11, pages 221 - 35, XP001538300 | |
| OPPOSITION | - HESS et al., "Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen", Cancer Immunol Immunother, (20060600), vol. 55, no. 6, doi:10.1007/s00262-005-0064-z, pages 672 - 83, XP019333249 | |
| OPPOSITION | - JEFFS et al., "A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA", Pharmaceutical Research, (20050000), vol. 22, doi:10.1007/s11095-004-1873-z, pages 362 - 372, XP019370801 | |
| OPPOSITION | - JEFFS et al., "A Scalable, Extrustion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA", Pharmaceutical Research, (20050000), vol. 22, no. 3, pages 362 - 372, XP002422317 | |
| OPPOSITION | - Lloyd B. Jeffs et al, "A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA", Pharmaceutical Research, Kluwer Academic Publishers-Plenum Publishers, NL, NL , (20050301), vol. 22, no. 3, doi:10.1007/s11095-004-1873-z, ISSN 1573-904X, pages 362 - 372, XP019370801 | |
| OPPOSITION | - Lloyd B. Jeffs ; Lorne R. Palmer ; Ellen G. Ambegia ; Cory Giesbrecht ; Shannon Ewanick ; Ian MacLachlan, "A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA", Pharmaceutical Research, NL , (20050301), vol. 22, no. 3, doi:10.1007/s11095-004-1873-z, ISSN 1573-904X, pages 362 - 372, XP019370801 | |
| OPPOSITION | - KLIBANOV A L, ET AL., "AMPHIPATHIC POLYETHYLENEGLYCOLS EFFECTIVELY PROLONG THE CIRCULATION TIME OF LIPOSOMES", FEBS Letters, ELSEVIER, AMSTERDAM., NL, NL , (19900701), vol. 268, no. 01, doi:10.1016/0014-5793(90)81016-H, ISSN 0014-5793, pages 235 - 237, XP001073450 | |
| OPPOSITION | - WILSON et al., "The Introduction of Poliovirus RNA into Cells via Lipid Vesicles (Liposomes", Cell, (19790000), vol. 17, doi:10.1016/0092-8674(79)90296-4, pages 77 - 84, XP023910555 | |
| OPPOSITION | - ZHOU X., ET AL., "SELF-REPLICATING SEMLIKI FOREST VIRUS RNA AS RECOMBINANT VACCINE.", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (19940101), vol. 12., no. 16., doi:10.1016/0264-410X(94)90074-4, ISSN 0264-410X, pages 1510 - 1514., XP002021790 | |
| OPPOSITION | - Minnaert An-Katrien et al, "Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across", Advanced Drug Delivery Reviews, Elsevier, Amsterdam , NL, Amsterdam , NL , (20210726), vol. 176, doi:10.1016/j.addr.2021.113900, ISSN 0169-409X, XP086773295 | |
| OPPOSITION | - Adriana O. Santos et al, "Design of peptide-targeted liposomes containing nucleic acids", Biochimica et Biophysica Acta, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20100301), vol. 1798, no. 3, doi:10.1016/J.BBAMEM.2009.12.001, ISSN 0005-2736, pages 433 - 441, XP002665487 | |
| OPPOSITION | - YAMAMOTO et al., "Current prospects for mRNA gene delivery", Eur J Pharm Biopharm, (20090300), vol. 71, no. 3, doi:10.1016/j.ejpb.2008.09.016, pages 484 - 9, XP025992169 | |
| OPPOSITION | - KIM et al., "Enhanced siRNA delivery using cationic liposomes with new polyarginine- conjugated PEG-lipid", International Journal of Pharmaceutics, (20100000), vol. 392, pages 141 - 147, XP027044515 | |
| OPPOSITION | - Schoenmaker Linde et al, "mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability", International Journal of Pharmaceutics, ELSEVIER, NL, NL , (20210501), vol. 601, doi:10.1016/j.ijpharm.2021.120586, ISSN 0378-5173, page 120586, XP055828800 | |
| OPPOSITION | - HEYES et al., "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", J. Controlled Release, (20050000), vol. 107, doi:10.1016/j.jconrel.2005.06.014, pages 276 - 287, XP008157522 | |
| OPPOSITION | - HEYES et al., "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", J. Contr. Release, (20050000), vol. 107, doi:10.1016/j.jconrel.2005.06.014, pages 276 - 287, XP008157522 | |
| OPPOSITION | - Heyes, J. et al, "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", Journal of Controlled Release, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20051003), vol. 107, no. 2, doi:10.1016/j.jconrel.2005.06.014, ISSN 0168-3659, pages 276 - 287, XP005076220 | |
| OPPOSITION | - OBATA et al., "Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo", J. Controlled Release, vol. 142, doi:10.1016/j.jconrel.2009.10.023, (20091025), pages 267 - 276, XP026905290 | |
| OPPOSITION | - Hassett Kimberly J. et al, "Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines", Molecular Therapy-Nucleic Acids, Cell Press, US, US , (20190415), vol. 15, doi:10.1016/j.omtn.2019.01.013, ISSN 2162-2531, pages 1 - 11, XP055815007 | |
| OPPOSITION | - ROUX et al., "AIDS virus envelope structure", Curr. Opin. In Structural Biology, (20070000), vol. 17, doi:10.1016/j.sbi.2007.03.008, pages 244 - 252, XP022032067 | |
| OPPOSITION | - Geall Andrew J. et al, "RNA: The new revolution in nucleic acid vaccines", Seminars in immunology, W.B. SAUNDERS COMPANY, PA., US, US , (19000101), vol. 25, no. 2, doi:10.1016/j.smim.2013.05.001, ISSN 1044-5323, pages 152 - 159, XP028694558 | |
| OPPOSITION | - Jeffrey B. Ulmer et al, "RNA-based vaccines", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20120418), vol. 30, no. 30, doi:10.1016/j.vaccine.2012.04.060, ISSN 0264-410X, pages 4414 - 4418, XP028520925 | |
| OPPOSITION | - José A. Melero, "Molecular Biology of Human Respiratory Syncytial Virus", Perspectives in Medical Virology, Elsevier , (20060101), vol. 14, pages 1 - 42, doi:10.1016/S0168-7069(06)14001-X, ISSN 0168-7069, XP055244030 | |
| OPPOSITION | - KARIKÓ KATALIN ET AL, "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.", Molecular Therapy, Nature Publishing Group, GB, GB , (20081101), vol. 16, no. 11, doi:10.1038/mt.2008.200, ISSN 1525-0024, pages 1833 - 1840, XP002598556 | |
| OPPOSITION | - ZIMMERMANN TRACY S ET AL, "RNAi-mediated gene silencing in non-human primates.", Nature, Nature Publishing Group UK, London, London, (20060504), vol. 441, no. 7089, doi:10.1038/nature04688, ISSN 0028-0836, pages 111 - 114, XP002412249 | |
| OPPOSITION | - ZHU et al., "Distribution and three-dimensional structure of AIDS virus envelope spikes", Nature, (20060600), vol. 441, no. 7095, doi:10.1038/nature04817, pages 847 - 52, XP037135198 | |
| OPPOSITION | - Benjamin Petsch et al, "Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection", Nature Biotechnology, Gale Group Inc., (20120101), vol. 30, no. 12, doi:10.1038/nbt.2436, ISSN 10870156, pages 1210 - 1216, XP055051005 | |
| OPPOSITION | - Ugur Sahin et al, "mRNA-based therapeutics — developing a new class of drugs", Nature Reviews Drug Discovery, Nature Pub. Group, vol. 13, no. 10, doi:10.1038/nrd4278, ISSN 14741776, pages 759 - 780, XP055159205 | |
| OPPOSITION | - Zolla-Pazner Susan; Cardozo Timothy, "Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design", Nature Reviews Immunology, Nature Publishing Group UK, London, London, (20100701), vol. 10, no. 7, doi:10.1038/nri2801, ISSN 1474-1733, pages 527 - 535, XP037134940 | |
| OPPOSITION | - DU et al., "The spike protein of SARS-CoV- a target for vaccine and therapeutic development", Nat Rev Microbiol, (20090300), vol. 7, doi:10.1038/nrmicro2090, pages 226 - 236, XP055302112 | |
| OPPOSITION | - Akinc Akin et al, "The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs", Nature Nanotechnology, Nature Pub. Group, Inc., London, London , (20191201), vol. 14, no. 12, doi:10.1038/s41565-019-0591-y, ISSN 1748-3387, pages 1084 - 1087, XP036953174 | |
| OPPOSITION | - SCHIBLI et al., "Class I and class II viral fusion protein structures reveal similar principles in membrane fusion", Molecular Membrane Biology, (20040000), vol. 21, doi:10.1080/09687860400017784, pages 361 - 371, XP009064617 | |
| OPPOSITION | - COMANDUCCI M, et al, "NadA, a novel vaccine candidate of Neisseria meningitidis", Journal of Experimental Medicine, Rockefeller University Press, US, US , (20020603), vol. 195, no. 11, doi:10.1084/jem.20020407, ISSN 0022-1007, pages 1445 - 1454, XP002272871 | |
| OPPOSITION | - Norbert Pardi, Et Al., "Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses", Journal of Experimental Medicine, Rockefeller University Press, US, US , (20180604), vol. 215, no. 6, doi:10.1084/jem.20171450, ISSN 0022-1007, pages 1571 - 1588, XP055545604 | |
| OPPOSITION | - FLEETON et al., "Self-replicative RNA vaccines elicit protection against influenza A virus, Respiratory Syncytial Virus, and a Tickborne Encephalitis Virus", Journal of Infectious Diseases, (20010000), vol. 183, doi:10.1086/319857, pages 1395 - 8, XP002224503 | |
| OPPOSITION | - W-Z Zhou et al, "RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization.", HUMAN GENE THERAPY, Mary Ann Liebert, Inc. Publishers, GB, GB , (19991101), vol. 10, no. 16, ISSN 1043-0342, pages 2719 - 2724, XP002660042 | |
| OPPOSITION | - SACHDEVA et al., "SPAAN: a software program for prediction of adhesins and adhesin-like proteins using neural networks", Bioinformatics, (20050215), vol. 21, no. 4, doi:10.1093/bioinformatics/bti028, pages 483 - 491, XP002350914 | |
| OPPOSITION | - GHILDYAL et al., "Central role of the respiratory syncytial virus matrix protein in infection", FEMS Microbiol. Rev., (20060000), vol. 30, doi:10.1111/j.1574-6976.2006.00025.x, pages 692 - 705, XP093030624 | |
| OPPOSITION | - Ghildyal Reena, Ho Adeline, Jans David A., "Central role of the respiratory syncytial virus matrix protein in infection", FEMS Microbiology Reviews, (20060901), vol. 30, no. 5, doi:10.1111/j.1574-6976.2006.00025.x, pages 692 - 705, XP093030624 | |
| OPPOSITION | - SCHLENDER et al., "Respiratory Syncytial Virus (RSV) Fusion Protein Subunit F2, Not Attachment Protein G, Determines the Specificity of RSV Infection", Journal of Virology, (20030000), vol. 77, doi:10.1128/JVI.77.8.4609-4616.2003, pages 4609 - 4616, XP002593949 | |
| OPPOSITION | - BRINGMANN et al., "RNA Vaccines in Cancer Treatment", Journal of Biomedicine and Biotechnology, (20100101), vol. 2010, doi:10.1155/2010/623687, pages 1 - 12, XP002765542 | |
| OPPOSITION | - Kawano, Et Al., "Effects of Polyethylene Glycol Spacer Length and Ligand Density on Folate Receptor Targeting of Liposomal Doxorubicin In Vitro", J. Drug. Delivery, doi:10.1155/2011/160967, (20110101), pages 1 - 6, J. Drug. Delivery, (20190925), XP055626067 | |
| OPPOSITION | - SONOKE et al., "Tumor Regression in Mice by Delivery of Bcl-2 Small Interfering RNA with Pegylated Cationic Liposomes", Cancer Research, (20080000), vol. 68, doi:10.1158/0008-5472.CAN-08-0127, pages 8843 - 8851, XP055046252 | |
| OPPOSITION | - Pascolo S, "Vaccination with messenger RNA", METHODS IN MOLECULAR MEDICINE, Humana Press, (20060101), ISSN 1543-1894, pages 23 - 40, XP009117840 | |
| OPPOSITION | - Bai Xilian et al, "Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles.", Expert opinion on biological therapy, Informa Healthcare, UK, UK , (20110701), vol. 11, no. 7, doi:10.1517/14712598.2011.585965, ISSN 1744-7682, pages 969 - 985, XP009175457 | |
| OPPOSITION | - PASCOLO S., "Messenger RNA-based vaccines", Expert Opin Biol Ther, (20040800), vol. 4, no. 8, doi:10.1517/14712598.4.8.1285, pages 1285 - 94, XP009095328 | |
| OPPOSITION | - Pascolo S, "Messenger RNA-based vaccines", EXPERT OPINION ON BIOLOGICAL THERAPY, Informa Healthcare, (20040801), vol. 4, no. 8, doi:10.1517/14712598.4.8.1285, ISSN 1471-2598, pages 1285 - 1294, XP009095328 | |
| OPPOSITION | - Deering Raquel P. et al, "Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.", Expert opinion on drug delivery, Informa Healthcare, UK, UK , (20140601), vol. 11, no. 6, doi:10.1517/17425247.2014.901308, ISSN 1744-7593, pages 885 - 899, XP009183535 | |
| OPPOSITION | - Morais Pedro, Adachi Hironori, Yu Yi-Tao, "The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines", Frontiers in Cell and Developmental Biology, vol. 9, doi:10.3389/fcell.2021.789427, XP055885272 | |
| OPPOSITION | - Karl-Josef Kallen et al, "A novel, disruptive vaccination technology: Self-adjuvanted RNActive® vaccines", Human vaccines & immunotherapeutics, (20131001), vol. 9, no. 10, doi:10.4161/hv.25181, ISSN 21645515, pages 2263 - 2276, XP055126357 | |
| OPPOSITION | - SCHLAKE T, THESS A, FOTIN-MLECZEK M, KALLEN K-J, "Developing mRNA-vaccine technologies", RNA BIOLOGY, (20121101), vol. 9, no. 11, doi:10.4161/rna.22269, ISSN 1547-6286, pages 1319 - 1330, XP002743467 | |
| OPPOSITION | - HASHIMOTO et al., "Neutralizing epitopes of RSV and palivizumab resistance in Japan", Fukushima J. Med. Sci., (20170000), vol. 63, doi:10.5387/fms.2017-09, pages 127 - 134, XP055527102 | |
| OPPOSITION | - Koichi Hashimoto, Mitsuaki Hosoya, "Neutralizing epitopes of RSV and palivizumab resistance in Japan", FUKUSHIMA JOURNAL OF MEDICAL SCIENCE, 福島医学会, doi:10.5387/fms.2017-09, (20170101), pages 127 - 134, FUKUSHIMA JOURNAL OF MEDICAL SCIENCE, URL: https://www.jstage.jst.go.jp/article/fms/63/3/63_2017-09/_pdf/-char/en, XP055527102 | |
| SEARCH | - MOCKEY M ET AL, "mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes", CANCER GENE THERAPY, (200709), vol. 14, no. 9, ISSN 0929-1903, pages 802 - 814, XP055007324 [A] 1-14 * page 804, column l, paragraph 4 * | |
